Assyro Team
Published January 14, 2026
Updated April 8, 2026
16 min read
Nitrosamine Control Strategy: From Risk Assessment to Confirmatory Testing
Quick Answer
A nitrosamine control strategy is the documented plan for preventing, detecting, and controlling nitrosamine impurities in pharmaceutical products. It encompasses root cause evaluation of amine + nitrite sources, process controls to prevent formation, validated analytical methods (primarily LC-MS/MS with sensitivity to 10% of acceptable intake limits), confirmatory testing of representative batches, and ongoing monitoring. FDA and EMA require control strategies to prioritize root cause elimination over end-product testing.
Key Takeaways
Key Takeaways
- FDA and EMA both require control strategies to prioritize root cause elimination of nitrosamine formation over end-product testing.
- Validated analytical methods (primarily LC-MS/MS) must demonstrate sensitivity to 10% of the applicable acceptable intake limit.
- Control strategies must address both drug substance-related nitrosamines and drug product-related nitrosamines formed during formulation or storage.
- Ongoing monitoring and lifecycle management are required; control strategies must be updated when manufacturing changes occur or new formation pathways are identified.
- A nitrosamine control strategy translates the findings of a risk assessment into actionable manufacturing controls, analytical methods, and specifications that ensure nitrosamine levels remain below acceptable intake (AI) limits throughout a product's lifecycle.
- The distinction between a risk assessment and a control strategy matters. A risk assessment identifies what could happen — which nitrosamines might form and through which pathways. A control strategy defines what you will do about it — the specific process modifications, material controls, analytical methods, and specifications that prevent or detect nitrosamine contamination.
- Regulatory agencies evaluate control strategies for both completeness and hierarchy of controls. A strategy that relies solely on end-product testing without addressing root causes will face scrutiny. FDA and EMA both emphasize that the preferred approach is eliminating the root cause of nitrosamine formation, with testing serving as a verification measure rather than the primary control.
- In this guide, you'll learn:
- Root cause evaluation methodology for nitrosamine formation
- Risk factor analysis for amine and nitrite sources
- Process control implementation strategies
- Analytical method requirements for confirmatory testing
- AI limits for specific nitrosamines (NDMA, NDEA, NMBA, and others)
- FDA and EMA regulatory timelines and submission requirements
Root Cause Evaluation
Root cause evaluation identifies the specific chemical and process-level mechanisms that allow nitrosamine formation. This goes beyond identifying whether amines and nitrites are present — it determines why they come into contact and under what conditions nitrosation occurs.
The Nitrosamine Formation Equation
Nitrosamines form when three conditions are met simultaneously:
Each component must be evaluated independently and in combination.
Amine Source Identification
| Amine Source | Examples | Risk Level | Control Approach |
|---|---|---|---|
| API structure | Secondary amines in ranitidine, metformin, rifampicin | High | NDSRI assessment; reformulation if feasible |
| Process intermediates | Dimethylamine from DMF degradation; diethylamine from TEA use | High | Solvent substitution; process redesign |
| Starting materials | Amine-containing starting materials with residual levels | Medium | Starting material specification; purge validation |
| Excipients | Croscarmellose sodium, povidone, sodium starch glycolate | Medium | Excipient supplier qualification; alternative excipient evaluation |
| Degradation products | Amine-bearing degradants from API or excipient breakdown | Medium | Stability monitoring; packaging optimization |
| Container closure | Amine migration from rubber stoppers, cap liners | Low-Medium | E&L studies; alternative closure systems |
Nitrosating Agent Source Identification
| Nitrosating Source | Examples | Risk Level | Control Approach |
|---|---|---|---|
| Sodium nitrite reagent | Direct use in API synthesis (e.g., diazotization reactions) | Critical | Process redesign; alternative reagents |
| Recycled solvents | Nitrite/nitrate accumulation in recovery operations | High | Dedicated solvents; recycling controls |
| Water | Nitrate/nitrite in purified water or WFI | Medium | Water system monitoring; nitrite specification |
| Excipients | Nitrite contamination in starch, cellulose derivatives | Medium | Excipient nitrite testing; supplier qualification |
| Gaseous NOx | Ambient nitrogen oxides; process atmosphere | Low-Medium | Inerting; environmental controls |
| Packaging | Nitrite leaching from rubber components | Low | E&L qualification; nitrite-free materials |
Favorable Conditions Analysis
| Condition | Nitrosation Promotion | Mitigation |
|---|---|---|
| Acidic pH (< 4) | Optimal for nitrosation kinetics | pH control > 4 where possible |
| Elevated temperature (> 60C) | Accelerates reaction kinetics | Temperature control; minimize thermal exposure |
| Prolonged contact time | Increases cumulative exposure | Process time limits; rapid processing |
| Aqueous environment | Facilitates ionic nitrosation | Minimize aqueous steps; dry processing |
| Catalytic metals | Certain metal ions catalyze nitrosation | Equipment qualification; metal-free vessels |
Process Control Implementation
Hierarchy of Controls
FDA and EMA both endorse a hierarchy of controls approach, prioritizing elimination over detection:
Level 1: Eliminate Root Cause (Most Preferred)
| Strategy | Implementation | Documentation |
|---|---|---|
| Remove nitrosating agent from process | Replace sodium nitrite with alternative reagent; use fresh solvents instead of recycled | Process change documentation; batch record update |
| Remove vulnerable amine from process | Alternative synthetic route; substitute reagents | Route change justification; regulatory filing |
| Switch to nitrite-free excipients | Qualify alternative excipient or nitrite-free grade | Excipient qualification report; stability data |
| Replace container closure | Nitrite-free rubber formulation; alternative closure | E&L study; stability data with new closure |
Level 2: Process Controls (Preferred)
| Strategy | Implementation | Documentation |
|---|---|---|
| pH control | Maintain pH > 4 during manufacturing steps where amines and nitrites could interact | In-process pH monitoring; batch record limits |
| Temperature control | Limit thermal exposure during vulnerable process steps | Temperature recording; validated ranges |
| Inerting | Nitrogen atmosphere to exclude NOx | Atmosphere monitoring; oxygen limits |
| Dedicated equipment | Prevent cross-contamination from previous campaigns | Equipment dedication policy; cleaning validation |
| Water system controls | Nitrite specification for process water (< 0.1 ppm) | Water monitoring program; trend analysis |
Level 3: Purification Controls
| Strategy | Implementation | Documentation |
|---|---|---|
| Additional washing steps | Aqueous washes to remove nitrosamine from organic phase | Process validation; purge factor data |
| Recrystallization | Additional crystallization to reduce impurity levels | Process development data; purge validation |
| Chromatographic purification | Column purification to remove specific nitrosamines | Method development; scale-up validation |
| Activated carbon treatment | Adsorptive removal of nitrosamines | Treatment validation; breakthrough studies |
Level 4: Specification and Testing (Least Preferred Alone)
| Strategy | Implementation | Documentation |
|---|---|---|
| Drug substance specification | Set limit at or below AI/MDD-derived specification | Validated analytical method; batch data |
| Drug product specification | Set limit at or below AI/MDD-derived specification | Validated analytical method; batch data |
| In-process testing | Test at critical manufacturing steps | Method validation; sampling plan |
| Batch release testing | Test every batch before release | Method validation; OOS investigation procedure |
Pro Tip
FDA reviewers will specifically ask why root cause elimination was not chosen if your control strategy relies primarily on Level 3 or Level 4 controls. Prepare a documented justification explaining why Level 1 or Level 2 controls are not technically feasible for your specific product and process. "Cost" alone is not an acceptable justification.
Analytical Methods for Nitrosamine Testing
LC-MS/MS: The Primary Method
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred analytical technique for nitrosamine quantification due to its sensitivity, selectivity, and multi-analyte capability.
Method requirements per FDA expectations:
| Parameter | Requirement | Rationale |
|---|---|---|
| Sensitivity (LOQ) | ≤ 10% of AI limit (adjusted for daily dose) | Must detect nitrosamines well below the specification |
| Specificity | Demonstrate separation from matrix interferences; use MRM transitions | Prevent false positives from co-eluting compounds |
| Linearity | R² ≥ 0.99 across range from LOQ to 200% of specification | Ensure accurate quantification across working range |
| Accuracy | 80-120% recovery at LOQ; 90-110% at specification level | Matrix effects must not suppress or enhance signal |
| Precision | RSD ≤ 20% at LOQ; ≤ 10% at specification level | Repeatable results within and between laboratories |
| Sample preparation | Appropriate for matrix (API, drug product, excipient) | Method must account for extraction efficiency |
Common LC-MS/MS configurations:
| Configuration | Application | Advantages |
|---|---|---|
| Reversed-phase LC + ESI+ MRM | Standard nitrosamine panel (NDMA, NDEA, NMBA, etc.) | Broad applicability; commercially available standards |
| HILIC + ESI+ MRM | Polar nitrosamines (NMEA, NMOR) | Better retention of polar analytes |
| GC-MS headspace | Volatile nitrosamines (NDMA, NDEA) in simple matrices | Very low detection limits for volatile species |
| GC-MS/MS | Complex matrices requiring additional selectivity | Enhanced specificity for challenging samples |
Multi-Analyte Method Design
A comprehensive nitrosamine method should simultaneously quantify all relevant nitrosamines based on the risk assessment:
| Analyte | MRM Transition (Typical) | AI (ng/day) | Typical LOQ Target |
|---|---|---|---|
| NDMA | 75 > 43 (quantifier); 75 > 58 (qualifier) | 96 | 2-5 ppb |
| NDEA | 103 > 75 (quantifier); 103 > 47 (qualifier) | 26.5 | 1-3 ppb |
| NMBA | 147 > 117 (quantifier); 147 > 73 (qualifier) | 96 | 2-5 ppb |
| NIPEA | 117 > 75 (quantifier); 117 > 43 (qualifier) | 26.5 | 1-3 ppb |
| NDIPA | 131 > 89 (quantifier); 131 > 43 (qualifier) | 26.5 | 1-3 ppb |
| NDBA | 159 > 103 (quantifier); 159 > 57 (qualifier) | 26.5 | 1-3 ppb |
| NMPA | 137 > 107 (quantifier); 137 > 66 (qualifier) | 26.5 | 1-3 ppb |
Method Validation Considerations
| Consideration | Challenge | Solution |
|---|---|---|
| Matrix effects | Drug substance or excipients can suppress/enhance ionization | Use isotopically labeled internal standards (d6-NDMA, d10-NDEA) |
| Artifact formation | Nitrosamines may form during sample preparation | Minimize acidic conditions; use cold sample processing |
| Cross-contamination | Sub-ppb levels are susceptible to laboratory contamination | Dedicated glassware; avoid DMF/DMA in mobile phases |
| Stability | Some nitrosamines degrade under light or elevated temperature | Process samples same day; protect from light; refrigerate |
| Reference standards | Certified standards required for each target analyte | Use certified reference materials (CRMs) from qualified suppliers |
Pro Tip
Artifact formation during sample preparation is a well-documented problem in nitrosamine analysis. If your sample preparation involves acidification of amine-containing matrices, you may generate nitrosamines in the sample solution that were not present in the original product. Always include control experiments (amine-containing matrix without nitrite, and nitrite-containing matrix without amine) to verify that no artifacts are formed during analysis.
Acceptable Intake Limits and Specification Setting
AI Limits for Specific Nitrosamines
| Nitrosamine | AI (ng/day) | Basis | Specification Calculation |
|---|---|---|---|
| NDMA | 96 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NDEA | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NMBA | 96 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NIPEA | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NDIPA | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NDBA | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NMPA | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NMEA | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NMOR | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| Uncharacterized | 18 | Cohort of concern TTC | 18 ng / MDD (g) = limit in ppm |
Specification Setting Worked Example
Product: Oral tablet, MDD = 320 mg (0.32 g), chronic use (lifetime exposure)
| Nitrosamine | AI (ng/day) | Specification (ppm) | Specification (ng/tablet) |
|---|---|---|---|
| NDMA | 96 | 96 / 0.32 = 300 ppb | 96 ng |
| NDEA | 26.5 | 26.5 / 0.32 = 82.8 ppb | 26.5 ng |
LOQ requirement for NDEA: ≤ 10% of 82.8 ppb = ≤ 8.3 ppb
Multiple Nitrosamines in a Single Product
When multiple nitrosamines are detected or at risk, FDA permits two approaches:
- Individual limits: Each nitrosamine controlled at its own AI-based specification (preferred)
- Aggregate control: Total nitrosamine content controlled if individual species are at very low levels relative to their AI limits
When using aggregate control, the contribution of each nitrosamine must be expressed as a fraction of its individual AI, and the sum must not exceed 1.0:
FDA and EMA Regulatory Timelines
FDA Timeline and Submission Requirements
| Milestone | FDA Expectation | Submission Vehicle |
|---|---|---|
| Risk assessment completion | Within 3 years of September 2020 guidance (by September 2023) | Not submitted unless requested |
| Confirmatory testing | For medium/high-risk products; completed as part of risk assessment | Retained for inspection |
| Control strategy implementation | For products where nitrosamines detected above 10% AI | SUPAC supplement (CBE-30 or PAS) |
| Specification addition | If nitrosamine specification added to drug substance or product | PAS (Prior Approval Supplement) for new specification |
| Process change | If manufacturing process modified to eliminate root cause | CBE-30 or PAS depending on change scope |
| Labeling update | Generally not required unless safety communication needed | CBE supplement |
EMA Timeline and Variation Requirements
| Milestone | EMA Expectation | Variation Type |
|---|---|---|
| Step 1: Risk evaluation | Completed by March 2021 (biologicals by July 2021) | Not submitted; retained for inspection |
| Step 2: Confirmatory testing | Completed by September 2023 (biologicals by July 2024) | Results retained |
| Step 3: Outcome reporting | If nitrosamines detected, submit variation | Type IB or Type II depending on findings |
| Change in specification | New nitrosamine specification | Type II variation |
| Process change | Manufacturing modification | Type IB or Type II variation |
| Change in finished product | Reformulation to eliminate risk | Type II variation |
Key Differences Between FDA and EMA Approaches
| Aspect | FDA | EMA |
|---|---|---|
| Scope | All drug products; expanded to all drug classes in 2023 | All medicinal products including biologicals |
| Risk assessment trigger | Vulnerable chemistries (amines + nitrosating conditions) | Broader: includes evaluation of all products |
| AI limit source | FDA-published AI table | Same AI values; derived from same carcinogenicity data |
| Submission requirement | SUPAC supplement for changes; risk assessment retained | Variation procedure for changes; Step 1/2 results reported |
| Interim limits | FDA initially permitted temporary higher limits during transition | EMA set clear deadline milestones |
| NDSRI approach | Explicit CPCA framework published | Aligned with FDA approach; cross-referenced guidance |
Confirmatory Testing Protocol
Batch Selection
| Selection Criterion | Minimum Requirement | Rationale |
|---|---|---|
| Number of batches | Minimum 3 commercial-scale batches | Statistical representation of process variability |
| Batch age | Include recent and retention samples | Assess both initial levels and formation over time during stability testing |
| Process representation | Include batches from all manufacturing sites | Site-specific process differences |
| Stability samples | Accelerated and long-term stability samples if available | Assess nitrosamine formation during storage |
Testing Protocol
- Sample preparation: Follow validated method; include matrix-matched standards and isotopically labeled internal standards
- System suitability: Verify instrument performance meets method requirements before each batch
- Bracketing: Include calibration standards at beginning and end of each analytical run
- Duplicate analysis: Analyze each sample in at least duplicate
- Control samples: Include blank (matrix without nitrosamine), positive control (spiked at specification level), and negative control (solvent blank)
Result Interpretation and Action
| Finding | Action Required | Regulatory Filing |
|---|---|---|
| All results < 10% of AI | Document results; no specification required; ongoing monitoring recommended | No filing required |
| Any result 10-100% of AI | Implement control strategy; set specification at AI; batch release testing | CBE-30 (FDA) or Type IB (EMA) |
| Any result > AI | Root cause investigation; immediate corrective action; evaluate patient risk | PAS (FDA) or Type II (EMA); possible market action |
Key Takeaways
References
Key Takeaways
- 1. Control strategy hierarchy matters: FDA and EMA both prefer root cause elimination over testing-only strategies. Document why higher-level controls are not feasible if you rely on specification and testing.
- 2. Identify all sources: Evaluate amines from API, excipients, degradation, and packaging. Evaluate nitrosating agents from reagents, water, solvents, and excipients. Evaluate conditions (pH, temperature, time) that promote nitrosation.
- 3. LC-MS/MS is the standard: Achieve LOQ at or below 10% of the AI-based specification. Use isotopically labeled internal standards to correct for matrix effects.
- 4. Prevent analytical artifacts: Nitrosamines can form during sample preparation if amine-containing matrices are exposed to acidic conditions. Include artifact control experiments.
- 5. AI limits are compound-specific: NDMA (96 ng/day) and NDEA (26.5 ng/day) have different limits. Uncharacterized nitrosamines default to the cohort of concern TTC of 18 ng/day.
- 6. Test representative batches: Minimum 3 commercial batches plus stability samples. Include batches from all manufacturing sites.
- 7. Regulatory pathways differ: FDA uses SUPAC supplements (CBE-30 or PAS). EMA uses variation procedures (Type IB or Type II). Plan the regulatory filing before implementing the control strategy.
- FDA Guidance: "Control of Nitrosamine Impurities in Human Drugs" (Version 3.0, March 2023)
- FDA Updated Table of Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (2023)
- EMA Questions and Answers on Nitrosamine Impurities (Updated 2023)
- EMA Article 5(3) Referral: Lessons Learned from Nitrosamine Impurities
- ICH M7(R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals
- ICH Q9(R1): Quality Risk Management
- 21 CFR 314.70: Supplements and Other Changes to an Approved NDA
- USP General Chapter <1469>: Nitrosamine Impurities
About the author
Assyro Team
Expert regulatory operations consultants helping pharmaceutical companies navigate complex compliance challenges.
See Assyro in action
Catch eCTD and eSTAR errors before your FDA review cycle.
Book a 20-minute demo. We'll validate a sample of your submission live and show you exactly where Assyro catches what your current QC misses.